Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT03203330 for Degenerative Osteoarthritis is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee Phase 3 535 Randomized Double-Blind Placebo-Controlled Multi-Center
Clinical Trial NCT03203330 is designed to study Treatment for Degenerative Osteoarthritis. It is a Phase 3 interventional study that is active, not recruiting, having started on 30 October 2018, with plans to enroll 535 participants. Led by Kolon TissueGene, Inc., it is expected to complete by 10 July 2026. The latest data from ClinicalTrials.gov was last updated on 30 December 2025.
Brief Summary
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ult...Show More
Detailed Description
This protocol is designed to assess the safety and efficacy of TG-C in treating symptoms of osteoarthritis of the knee and determining disease modifying effects of TG-C. This study is intended for the treatment of patients with KL Grade 2 and 3 osteoarthritis and OARSI JSN Grade 1 and 2. Assessments will be made on both the symptomatic effects of pain (VAS), function (WOMAC), and Quality of Life (SF-12) as well as th...Show More
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee
Conditions
Degenerative OsteoarthritisPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- TGC-12301
NCT ID Number
Start Date (Actual)
2018-10-30
Last Update Posted
2025-12-30
Completion Date (Estimated)
2026-07-10
Enrollment (Estimated)
535
Study Type
Interventional
PHASE
Phase 3
Status
Active, not recruiting
Keywords
knee
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Quadruple
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active ComparatorActive Treatment (TG-C) TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection | TG-C 2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1. |
Placebo ComparatorPlacebo Control (Normal Saline) Normal saline, single 2 mL intraarticular injection | Placebo Control 2 mL normal saline injection |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in Knee Function as Assessed by the Western Ontario and McMaster Universities Index (WOMAC) | Assessment of change from baseline in target knee function using the WOMAC Osteoarthritis Index. The WOMAC is a proprietary set of standardized questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee including pain, stiffness, and physical functioning of the joints. The response to the questions is in the form of a checked box associated with the response; None, Mild, Moderate, Severe and Extreme. | 12 months |
Change in Knee Pain as Assessed by VAS | Assessment of change from baseline in target knee pain using the Visual Analog Scale (VAS). The VAS is a method for the assessment of the intensity of pain. The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain. | 12 months |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
MRI Assessment of Target Knee | Evaluation of the features of OA, as determined by structural changes of the knee joint, assessed by MRI | 12 months |
PCS of the SF-12 Questionnaire | Evaluation the Health-Related Quality of Life (HRQoL) as measured by the physical component score (PCS) of the 12-Item Short-Form Health Survey version 2 (SF-12v2®) questionnaire | 12 months |
WOMAC Total Score | Evaluation of the efficacy of TG-C with regard to knee function via WOMAC total score | 24 months |
Health Assessment Questionnaire Disability Index | Evaluation of the HRQoL as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI) | 12 months |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
40 Years
Eligible Sexes
All
- Aged 40 or older
- BMI between 18.5 and 40
- KL Grade 2 or 3 knee OA
- OARSI Grade 1 or 2 medial JSN
- Pain >= 40 on VAS scale
- Written informed consent
- Using birth control
- Knee symptoms that result in difficulty or inability to walk
- Knee effusion >2+
- Has Grade 3 OARSI JSN
- Has a score of 0 or >=5 on the cartilage feature of the WORMS at Screening
- MRI exam indicates fracture or tumor
- Has a positive result on RCR testing at Screening
- Has taken NSAIDS with 14 days of baseline
- Has taken steroidal anti-inflammatory medication within 2 months of baseline
- Chronic (>21 days) narcotic use
- Recent history (within 1 year) of drug or alcohol abuse
- Pregnant or lactating
- Has received injection to target knee within 2 months prior to study entry
- History of various disorders of the knee including but not limited to rheumatoid arthritis, psoriatic arthritis, autoimmune OA, chondrocalcinosis, gout, hemochromatosis, villonodular synovitis, or synovial chondromatosis
- Severe hip osteoarthritis ipsilateral to the target knee
- Ongoing infection disease including but not limited to HIV, Hepatitis B or C.
- Clinically significant congestive heart failure hepatic disease, kidney disease, adrenal insufficiency, acromegaly, uncontrolled hyper- or hypothyroidism, or non-specified uncontrolled endocrine disorder
- Uncontrolled diabetes based on a HbA1c > 8% at screening
No contact data.
44 Study Locations in 1 Countries
Alabama
Jeffrey Davis, Birmingham, Alabama, 35205, United States
Bradly Goodman, Birmingham, Alabama, 35235, United States
Arizona
Saima Chohan, Phoenix, Arizona, 85032, United States
Nebojsa Skrepnik, Tucson, Arizona, 85712, United States
California
Diraj Karnani, Apple Valley, California, 92307, United States
Dan La, Covina, California, 91722, United States
Scott Hacker, La Mesa, California, 91942, United States
Eric Grigsby, Napa, California, 94558, United States
Arthur Mabaquiao, San Diego, California, 92108, United States
Timothy Davis, Santa Monica, California, 90403, United States
Tien-I Su, Whittier, California, 90602, United States
District of Columbia
Mehul Desai, Washington D.C., District of Columbia, 20006, United States
Florida
David Billmeier, Daytona Beach, Florida, 32117, United States
Mercedes Ponce De Leon, Miami, Florida, 33135, United States
Aurelio Torres-Consuegra, Miami, Florida, 33144, United States
Edgar Gonzalez, Miami, Florida, 33144, United States
Cathy Barnes, New Port Richey, Florida, 34652, United States
Howard Chipman, Oldsmar, Florida, 34677, United States
Richard Linn, Sunrise, Florida, 33351, United States
Anand Patel, Winter Park, Florida, 32789, United States
Georgia
Sandeep Vaid, Newnan, Georgia, 30265, United States
Illinois
Dennis Levinson, Chicago, Illinois, 60607, United States
Manish Jain, Chicago, Illinois, 60640, United States
Hythem Shadid, Oak Brook, Illinois, 60523, United States
Louisiana
Adil Fatakia, Marrero, Louisiana, 70072, United States
Maryland
James Nace, Baltimore, Maryland, 21215, United States
Nebraska
Melvin Churchill, Lincoln, Nebraska, 68516, United States
New York
Jason Oh, New York, New York, 10075, United States
North Carolina
Brett Gilbert, Durham, North Carolina, 27704, United States
Jeremy Hoff, Wilmington, North Carolina, 28412, United States
Oklahoma
Yogesh Mittal, Tulsa, Oklahoma, 74104, United States
Pennsylvania
Alan Kivitz, Duncansville, Pennsylvania, 16635, United States
South Carolina
Edward Tavel, Columbia, South Carolina, 29206, United States
Eric Loudermilk, Greenville, South Carolina, 29601, United States
Tennessee
Harvey Bowles, Nashville, Tennessee, 37203, United States
Texas
Daneshvari Solanki, Bellaire, Texas, 77401, United States
Amr Morsy, Dallas, Texas, 75240, United States
Haresh Boghara, DeSoto, Texas, 75115, United States
Aldo Maspons, El Paso, Texas, 79225, United States
Subodh Bhuchar, Houston, Texas, 77099, United States
Brian MacGillivray, San Antonio, Texas, 78258, United States
Utah
John Hemmersmeier, South Ogden, Utah, 84405, United States
Virginia
Kristen Holtz, Charlottesville, Virginia, 22901, United States
Mark Hermann, Danville, Virginia, 24541, United States